A drug company may advertise a product as a way to help treat cancer but, as long as the drug is approved by the FDA, it will likely still be marketed as a treatment for cancer, according to new research from researchers at the University of California, San Diego.
The study is one of the first to link drug advertising to cancer treatment.
The researchers found that, for the first time, drug companies often advertised cancer treatments as a cure rather than a treatment.
In some cases, drug advertisements may even promote cancer treatments that are not actually effective.
Drug companies may have a financial incentive to market cancer treatments and make the claims that they are the best way to treat cancer.
But it’s not clear why, said lead author Matthew G. Lefkowitz, a research associate in UCSD’s Department of Biological Sciences.
“We were curious about why drug companies were advertising cancer as a therapeutic when there was no proof it was effective,” he said.
“Some of these things we have found in previous studies are very important, but it’s also very important to note that there is a lot more research to do on this,” Lefksowitz said.
Researchers examined a large number of FDA-approved cancer drugs, which include several new or approved drugs for the treatment of melanoma, prostate cancer, and other cancers.
The drug companies did not have to disclose whether the drugs were approved for treatment of cancer or whether they were not.
They also looked at drug advertisements that were made for various other diseases, such as diabetes, and used data from drug advertisements made by companies like Amgen, AstraZeneca, Pfizer, and Valeant Pharmaceuticals.
“These are not the only ways to advertise cancer treatments,” Laffkowitz said, “but they’re the most common.”
A number of drugs are marketed as treatment for certain diseases, including cancers, that were never approved for any other purpose, including a treatment that can be used to treat multiple diseases, he said, including those related to Parkinson’s disease, hepatitis C, diabetes, obesity, and cancer.
The drugs that have not been approved for other purposes are often called orphan drugs.
“This is not just about one drug, or one cancer treatment, or even one drug for a particular disease,” Lufkowitz explained.
“This is really about the advertising of cancer treatments.”
The study also found that drug companies may not disclose whether or not the drugs are effective for other diseases.
“When it comes to drug safety, there are different kinds of safety issues,” he added.
“There are issues with potential side effects, there is issues with the drug going off as prescribed, there’s issues with toxicity, and there’s other issues that you can’t control, like how much you expose people to the drug.”
Lefksowets reported his findings in the journal PLOS ONE.
Lefkowsky is a co-author on the study, which was funded by the National Institutes of Health, the U.S. Department of Veterans Affairs, and the National Institute of Health.
He is also the principal investigator for a study that looked at the marketing of drugs marketed to treat diabetes.
The drug companies could be looking at other avenues to advertise their products, including the fact that they can promote other treatments, the researchers said.
Leblanc is a freelance journalist based in the U and a freelance health writer based in California.
Follow him on Twitter at @leblanc,or at his website.
Follow TechRadars on Facebook and Twitter at techradar.